Tortugas Neuroscience Appointed New Financial Chief
The biotechnology firm has named Ramzi Benamar to the position of chief financial officer.
Updated on Sept. 25, 2026 in People

Tortugas Neuroscience has officially appointed Ramzi Benamar to serve as the company's chief financial officer. Benamar joins the organization as an established biotechnology executive.
Why it matters
This executive leadership change positions Tortugas Neuroscience with new financial oversight. The move reflects the company's efforts to strengthen its management team within the competitive biotechnology sector.
The appointment involves one executive transition to the role of chief financial officer. No other fiscal or operational metrics were provided by the company during this announcement.
The players
Ramzi Benamar
Ramzi Benamar is an experienced biotechnology executive who has been appointed as the chief financial officer of Tortugas Neuroscience.
Tortugas Neuroscience
Tortugas Neuroscience is a biotechnology company based in the United States that focuses on the research and development of neurological therapies.
The details
Tortugas Neuroscience announced the addition of Ramzi Benamar to its executive suite. As a seasoned biotechnology executive, Benamar brings his professional background to the firm's financial operations.
Timeline
September 25, 2026: Tortugas Neuroscience announced the appointment of Ramzi Benamar as chief financial officer.
Market Landscape
This leadership appointment follows the broader pattern of specialized talent recruitment within the biotechnology industry to support long-term research goals. By securing an experienced executive, Tortugas Neuroscience is positioning itself to better navigate the financial complexities of the sector.
This internal corporate change does not have an immediate impact on product availability or retail pricing for the average consumer. Investors and stakeholders should monitor upcoming quarterly filings for any shifts in the firm's financial strategy under the new executive.
The takeaway
Leadership changes at the executive level often signal a pivot in a company's financial strategy or capital allocation priorities. Shareholders should watch how these management shifts influence the company's research milestones and budget management in the coming months.
Further reading
For more on industry leadership changes, visit the People section.
Source note: This article includes information reported by Thepharmaletter.






